WASHINGTON (dpa-AFX) - Novavax Inc. (NVAX), on Monday announced positive results from a study of its Covid-19 vaccine NVX-CoV2373 and influenza vaccine Seqirus being administered simultaneously.
According to the company, the results suggest simultaneous vaccination may be a 'viable immunization strategy.'
The protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.
As part of Novavax' Phase 3 clinical trial of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate, in the United Kingdom, 431 volunteers were also enrolled in a co-administration sub-study, led by researchers at St George's, University of London and St George's Hospital, London.
All received an approved seasonal influenza vaccine with approximately half the participants co-vaccinated with NVX-CoV2373 while the remainder received placebo. The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX-CoV2373 alone.
Earlier on Monday, Novavax said NVX-CoV2373, its Covid-19 vaccine candidate, met the primary end point in late-stage study. The phase 3 study of NVX-CoV2373, dubbed Prevent-19, showed overall efficiency of 90.4%, achieving its primary endpoint.
'As the next influenza season approaches and people still need a primary COVID-19 vaccine series or a booster, separate healthcare visits to cover both COVID-19 and influenza vaccinations will be burdensome,' said Gregory Glenn, M.D., President of Research and Development, Novavax. 'As the first clinical study to evaluate safety, immunogenicity, and efficacy of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine, these results demonstrate the promising opportunity for concomitant vaccination, which may improve the uptake of both vaccines.'
Copyright RTT News/dpa-AFX
© 2021 AFX News
